Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06262321 | Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax(DRO2301) | recruiting | Phase 2 | 48 | University of RochesterOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06868485 | A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 40 | Wayshine Biopharm, Inc.INDUSTRY | 3 | Sep 8, 2025 |
| clinicaltrials |
| NCT07145333 | Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms(Drug-SNP) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07158840 | AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment(AGA TKI NSCLC) | not yet recruiting | Phase 2 | 60 | AkesoINDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06127303 | Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC | recruiting | Phase 2 | 54 | Shanghai Chest HospitalOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07156604 | Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05318573 | A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 120 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07153770 | Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 34 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06784791 | Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)(NEOpredict-EGF) | recruiting | Phase 2 | 20 | University Hospital, EssenOTHER | 3 | Aug 29, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT05796089 | Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy(CHEST RT) | active not recruiting | Phase 2 | 35 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | not yet recruiting | Phase 1 / Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07139041 | Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC | not yet recruiting | Phase 2 | 69 | Chang ChenOTHER | 0 | Aug 24, 2025 | clinicaltrials |
| NCT04495153 | CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC | active not recruiting | Phase 2 | 90 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07134413 | QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC | not yet recruiting | Phase 2 | 77 | Guangdong Association of Clinical TrialsOTHER | 0 | Aug 21, 2025 | clinicaltrials |
| NCT07129161 | Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC | not yet recruiting | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07130032 | Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade(reICB) | recruiting | Phase 2 | 90 | EuroCityClinic LLCNETWORK | 1 | Aug 19, 2025 | clinicaltrials |
| NCT06907615 | A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 243 | Shanghai Henlius BiotechINDUSTRY | 2 | Aug 17, 2025 | clinicaltrials |
| NCT03620669 | 1st Line Durvalumab in PS 2 NSCLC Patients | active not recruiting | Phase 2 | 48 | Swiss Cancer InstituteOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07109401 | Perioperative Immunotherapy for Resectable Limited-Stage SCLC | recruiting | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05787613 | A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients | active not recruiting | Phase 2 | 132 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106528 | Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 128 | Peking Union Medical College HospitalOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT07103408 | A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05442060 | To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer(EGFR) | recruiting | Phase 2 | 60 | OBI Pharma, IncINDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07101627 | A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy | not yet recruiting | Phase 2 | 149 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06417008 | A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 1,080 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06897046 | Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC | recruiting | Phase 2 | 90 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07097948 | Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033(Adjuvant) | not yet recruiting | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT05078931 | A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients | active not recruiting | Phase 2 | 35 | Shanghai Chest HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07014202 | Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy | recruiting | Phase 2 | 224 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07092137 | Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer | not yet recruiting | Phase 2 | 116 | Guangzhou Institute of Respiratory DiseaseOTHER | 0 | Jul 29, 2025 | clinicaltrials |
| NCT06864624 | Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC(WU-KONG20) | recruiting | Phase 2 | 27 | Tang-Du HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07063329 | Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive | not yet recruiting | Phase 1 / Phase 2 | 108 | Avistone Pharmaceutical（Ningbo）Co., LTD.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07085182 | Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study | recruiting | Phase 2 | 20 | Zibo Municipal HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07086326 | A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC(NEOINSPIRE) | not yet recruiting | Phase 2 | 164 | Yang Fan, MDOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07086456 | Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07083687 | Lorlatinib in ROS1+ NSCLC With Brain Metastasis | not yet recruiting | Phase 2 | 21 | Hunan Cancer HospitalOTHER | 0 | Jul 24, 2025 | clinicaltrials |
| NCT03753685 | X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases | active not recruiting | Phase 2 | 27 | Fudan UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05894889 | Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC | active not recruiting | Phase 2 | 70 | Peking UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06951464 | A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC | recruiting | Phase 2 | 40 | Sichuan UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04136535 | Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC(PCA) | recruiting | Phase 2 | 105 | Fudan UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT06951399 | Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 30 | Rabin Medical CenterOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07076693 | Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC） | active not recruiting | Phase 2 / Phase 3 | 97 | Shanghai Chest HospitalOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07076914 | Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy(PPI-PROTECT) | not yet recruiting | Phase 2 | 58 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07076095 | A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer | not yet recruiting | Phase 2 | 200 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Jul 21, 2025 | clinicaltrials |
| NCT03670056 | Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy | active not recruiting | Phase 2 | 25 | Yale UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06709859 | Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC | recruiting | Phase 2 | 30 | Shandong Public Health Clinical CenterOTHER_GOV | 1 | Jul 17, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 8, 2025source: clinicaltrials